The EU’s Pharma Strategy in a Post COVID-19 World

European Union (EU) health ministers met this week (May 12, 2020) to begin discussing a pharmaceutical strategy for the EU, a move originally put forth in January of this year (2020), but which now will take into account the EU’s economic recovery plan in the wake of the novel coronavirus (COVID-19) pandemic. What has been discussed thus far?

The EU’s pharmaceutical strategy

Before the COVID-19 outbreak, the European Commission had put on its agenda for 2020 a work program to develop an EU-based pharmaceutical strategy. This week (May 12, 2020), the EU health ministers met via video conference to discuss access to medicines and to provide initial feedback for its Pharmaceutical Strategy for Europe. The meeting, originally to be held in Zagreb, Croatia, was chaired by Dr Vera Katalinić-Janković, Assistant Minister of Health of Croatia, with participation from Stella Kyriakides, the European Commissioner of Health and Food Safety, and Professor Guido Rasi, Executive Director of the European Medicines Agency.

In her opening remarks, Commissioner Kyriakides highlighted universality and access as two overarching goals to enable security of supply of medicines. Both Commissioner Kyriakides and the EMA’s Executive Director Rasi stressed the importance of early detection of shortages and increased production in the EU in order to ensure the security of the supply of medicines on the internal market.

“The coronavirus pandemic has showed us more than ever that we need develop a new EU pharmaceutical strategy to ensure affordability, sustainability and security of supply,” said Dr. Katalinić-Janković in a May 12, 2020 statement. “We need to establish the means to produce medicines within the EU and ensure that citizens and hospitals can have access to essential medicines at all times. We have a collective responsibility to put the patient at the center and I welcome today’s [May 12, 2020] constructive discussion with Ministers.”

Overall, the EU health ministers engaged in a discussion on reliable and continuous access to medicines, particularly in light of the COVID-19 pandemic that highlighted and worsened the existing problem with supply of important medicines in Europe. The discussion emphasized that the spread of COVID-19 has put an “enormous strain” on EU member states’ healthcare systems, and the EU health ministers stressed the importance to keep strengthening the cooperation between EU member states and the European Commission to ensure accessibility and affordability of medicines. Moreover, the EU health ministers exchanged views on the ongoing development of the new Pharmaceutical Strategy for Europe and provided initial informal inputs for it. They focused on the link between the Pharmaceutical Strategy for Europe and Industrial Strategy, which was published in March (March 2020) and on the EU’s announced Economic Recovery Plan. Finally, the EU ministers reflected on the possibility for strengthening the communication between national authorities and stakeholders, specifically in establishing an appropriate platform for regular dialogue for specific topics.

In anticipation of the meeting of the EU health ministers, the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents innovator, research-based pharmaceutical companies in Europe, issued a statement on what it hopes will be considered in ongoing discussions of a pharmaceutical strategy for the EU.

“Now more than ever is it crucial that all actors work together to forge a Pharmaceutical Strategy linked to both the industrial strategy and recovery plan that can drive Europe’s economic recovery while building its resilience to this and future health threats,” said EFPIA Director General, Nathalie Moll, in an May 11, 2020 statement. “At EFPIA, we strongly support a regular, multi-stakeholder dialogue with the EU and Member States to learn the lessons of COVID-19, building on the partnerships and new ways of working forged during the crisis. This collaborative approach can help Europe strengthen our research eco-system, increase our resilience, deliver better health outcomes for citizens and drive our economic recovery.”


Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look.

In the Spotlight: FDA’s Inspections of Foreign Drug Mfg Facilities

The FDA’s inspection process for foreign drug-manufacturing facilities came under scrutiny once again with Congress holding a hearing questioning the frequency and quality of FDA’s foreign drug inspections. What may be next?

Manufacturing Fallout of Novo’s $16.5-Billion Acquisition of Catalent

The CDMO/CMO sector had a major shakeup with Novo Holdings, the parent company of Novo Nordisk, announcing it had agreed to acquire Catalent for $16.5 billion. What is the strategy behind the deal and the implications on a manufacturing basis?

The CDMO/CMO and Suppliers’ Report: Small-Molecule APIs

Which CDMOs/CDMO are expanding manufacturing capacity for intermediates and small-molecule active pharmaceutical ingredients (APIs)? DCAT Value Chain Insights gives a roundup of recently announced, in-progress, and completed expansions.